Aditya Bardia MD, MPH

Aditya Bardia, MD, MPH, iis Professor of Medicine at the David Geffen School of Medicine at UCLA and the director of Translational Research Integration and co-director of the Breast Cancer Disease Site Group at the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California. He also serves as Director of the Breast Oncology Program and Assistant Chief of Translational Research Integration in the Division of Hematology/Oncology.

Dr. Bardia received his medical degree from the All India Institute of Medical Sciences (AIIMS) in New Delhi, India, and his Master of Public Health from the University of Iowa College of Public Health. Dr. Bardia completed his residency at the Mayo Clinic in Rochester, Minnesota, followed by a fellowship in medical oncology at Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland.

Dr. Bardia has a distinguished record of leading clinical trials investigating the role of targeted therapy combinations for breast cancer, particularly antibody drug conjugates. He led the development of sacituzumab govitecan, the first antibody drug conjugate approved for patients with metastatic triple negative breast cancer, as well as others including trastuzumab deruxtecan and datopotamab deruxtecan. He also led the clinical development of elacestrant, the first oral SERD approved for patients with metastatic hormone receptor-positive breast cancer. Dr. Bardia’s translational team also helped discover the role of acquired ESR1 mutations in mediating endocrine resistance, RB1 mutations in mediating CDK 4/6i resistance and TOP1 mutations in mediating antibody drug conjugate resistance.

Dr. Bardia has received several awards including the Outstanding Award for Research Excellence at Mayo Clinic, the Young Investigator Award from the American Society of Clinical Oncology (ASCO), the Distinguished Researcher Award from the Massachusetts Society of Clinical Oncologists (MASCO), and the Douglas Family Foundation prize for excellence in oncology research.